CA 15-3

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 2236629 Experts worldwide ranked by ideXlab platform

Jan C. Grutters - One of the best experts on this subject based on the ideXlab platform.

  • Change in Serum Biomarker CA 15-3 as an Early Predictor of Response to Treatment and Survival in Hypersensitivity Pneumonitis
    Lung, 2020
    Co-Authors: Sofia A Moll, Ivo A. Wiertz, Adriane D.m. Vorselaars, Henk J.t. Ruven, C. H. M. Moorsel, Jan C. Grutters
    Abstract:

    Background Hypersensitivity pneumonitis (HP) is an interstitial lung disease with a heterogeneous course of disease and treatment response. CAncer antigen 15-3 (CA 15-3), part of mucin 1, is believed to reflect epithelial cell injury and lung permeability and could be a potential biomarker for treatment response in HP. Objective To assess the value of CA 15-3 as a predictive biomarker in non-fibrotic and fibrotic HP during immunosuppressive therapy. Design Serum levels of CA 15-3 and pulmonary function tests (PFTs) were retrospectively retrieved from 48 HP patients treated with prednisone or cyclophosphamide at initiation of therapy (baseline), after 3 and 6 months. Pearson's correlation coefficient was computed to assess correlations between change in serum levels and PFT. Survival was evaluated using Kaplan–Meier curves. Results After 6 months of immunosuppressive therapy CA 15-3 levels decreased signifiCAntly compared to baseline ( p  = 0.001). Change in CA 15-3 after 6 months correlated with FVC change ( r  =  − 0.469; p  = 0.001). Correlations with FVC change were observed in prednisone-treated HP ( r  =  − 0.514; p  = 0.005) and fibrotic HP ( r  =  − 0.417; p  = 0.007). Three-month CA 15-3 change correlated with 6-month FVC change ( r  =  − 0.599; p  

  • Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis.
    Biomarkers in medicine, 2020
    Co-Authors: Sofia A Moll, Ivo A. Wiertz, Adriane D.m. Vorselaars, Pieter Zanen, Henk J.t. Ruven, Coline H.m. Van Moorsel, Jan C. Grutters
    Abstract:

    Aim: CAncer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year follow-up were evaluated by a mixed model in 132 IPF treated with pirfenidone or nintedanib. Results: Increased baseline (median: 56 kU/l) and follow-up CA 15-3 levels were inversely associated with forced vital CApacity and diffusing CApacity of the lung for CArbon monoxide (estimates respectively: -5.21 and -4.69; p 

Sofia A Moll - One of the best experts on this subject based on the ideXlab platform.

  • Change in Serum Biomarker CA 15-3 as an Early Predictor of Response to Treatment and Survival in Hypersensitivity Pneumonitis
    Lung, 2020
    Co-Authors: Sofia A Moll, Ivo A. Wiertz, Adriane D.m. Vorselaars, Henk J.t. Ruven, C. H. M. Moorsel, Jan C. Grutters
    Abstract:

    Background Hypersensitivity pneumonitis (HP) is an interstitial lung disease with a heterogeneous course of disease and treatment response. CAncer antigen 15-3 (CA 15-3), part of mucin 1, is believed to reflect epithelial cell injury and lung permeability and could be a potential biomarker for treatment response in HP. Objective To assess the value of CA 15-3 as a predictive biomarker in non-fibrotic and fibrotic HP during immunosuppressive therapy. Design Serum levels of CA 15-3 and pulmonary function tests (PFTs) were retrospectively retrieved from 48 HP patients treated with prednisone or cyclophosphamide at initiation of therapy (baseline), after 3 and 6 months. Pearson's correlation coefficient was computed to assess correlations between change in serum levels and PFT. Survival was evaluated using Kaplan–Meier curves. Results After 6 months of immunosuppressive therapy CA 15-3 levels decreased signifiCAntly compared to baseline ( p  = 0.001). Change in CA 15-3 after 6 months correlated with FVC change ( r  =  − 0.469; p  = 0.001). Correlations with FVC change were observed in prednisone-treated HP ( r  =  − 0.514; p  = 0.005) and fibrotic HP ( r  =  − 0.417; p  = 0.007). Three-month CA 15-3 change correlated with 6-month FVC change ( r  =  − 0.599; p  

  • Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis.
    Biomarkers in medicine, 2020
    Co-Authors: Sofia A Moll, Ivo A. Wiertz, Adriane D.m. Vorselaars, Pieter Zanen, Henk J.t. Ruven, Coline H.m. Van Moorsel, Jan C. Grutters
    Abstract:

    Aim: CAncer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year follow-up were evaluated by a mixed model in 132 IPF treated with pirfenidone or nintedanib. Results: Increased baseline (median: 56 kU/l) and follow-up CA 15-3 levels were inversely associated with forced vital CApacity and diffusing CApacity of the lung for CArbon monoxide (estimates respectively: -5.21 and -4.69; p 

Henk J.t. Ruven - One of the best experts on this subject based on the ideXlab platform.

  • Change in Serum Biomarker CA 15-3 as an Early Predictor of Response to Treatment and Survival in Hypersensitivity Pneumonitis
    Lung, 2020
    Co-Authors: Sofia A Moll, Ivo A. Wiertz, Adriane D.m. Vorselaars, Henk J.t. Ruven, C. H. M. Moorsel, Jan C. Grutters
    Abstract:

    Background Hypersensitivity pneumonitis (HP) is an interstitial lung disease with a heterogeneous course of disease and treatment response. CAncer antigen 15-3 (CA 15-3), part of mucin 1, is believed to reflect epithelial cell injury and lung permeability and could be a potential biomarker for treatment response in HP. Objective To assess the value of CA 15-3 as a predictive biomarker in non-fibrotic and fibrotic HP during immunosuppressive therapy. Design Serum levels of CA 15-3 and pulmonary function tests (PFTs) were retrospectively retrieved from 48 HP patients treated with prednisone or cyclophosphamide at initiation of therapy (baseline), after 3 and 6 months. Pearson's correlation coefficient was computed to assess correlations between change in serum levels and PFT. Survival was evaluated using Kaplan–Meier curves. Results After 6 months of immunosuppressive therapy CA 15-3 levels decreased signifiCAntly compared to baseline ( p  = 0.001). Change in CA 15-3 after 6 months correlated with FVC change ( r  =  − 0.469; p  = 0.001). Correlations with FVC change were observed in prednisone-treated HP ( r  =  − 0.514; p  = 0.005) and fibrotic HP ( r  =  − 0.417; p  = 0.007). Three-month CA 15-3 change correlated with 6-month FVC change ( r  =  − 0.599; p  

  • Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis.
    Biomarkers in medicine, 2020
    Co-Authors: Sofia A Moll, Ivo A. Wiertz, Adriane D.m. Vorselaars, Pieter Zanen, Henk J.t. Ruven, Coline H.m. Van Moorsel, Jan C. Grutters
    Abstract:

    Aim: CAncer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year follow-up were evaluated by a mixed model in 132 IPF treated with pirfenidone or nintedanib. Results: Increased baseline (median: 56 kU/l) and follow-up CA 15-3 levels were inversely associated with forced vital CApacity and diffusing CApacity of the lung for CArbon monoxide (estimates respectively: -5.21 and -4.69; p 

Adriane D.m. Vorselaars - One of the best experts on this subject based on the ideXlab platform.

  • Change in Serum Biomarker CA 15-3 as an Early Predictor of Response to Treatment and Survival in Hypersensitivity Pneumonitis
    Lung, 2020
    Co-Authors: Sofia A Moll, Ivo A. Wiertz, Adriane D.m. Vorselaars, Henk J.t. Ruven, C. H. M. Moorsel, Jan C. Grutters
    Abstract:

    Background Hypersensitivity pneumonitis (HP) is an interstitial lung disease with a heterogeneous course of disease and treatment response. CAncer antigen 15-3 (CA 15-3), part of mucin 1, is believed to reflect epithelial cell injury and lung permeability and could be a potential biomarker for treatment response in HP. Objective To assess the value of CA 15-3 as a predictive biomarker in non-fibrotic and fibrotic HP during immunosuppressive therapy. Design Serum levels of CA 15-3 and pulmonary function tests (PFTs) were retrospectively retrieved from 48 HP patients treated with prednisone or cyclophosphamide at initiation of therapy (baseline), after 3 and 6 months. Pearson's correlation coefficient was computed to assess correlations between change in serum levels and PFT. Survival was evaluated using Kaplan–Meier curves. Results After 6 months of immunosuppressive therapy CA 15-3 levels decreased signifiCAntly compared to baseline ( p  = 0.001). Change in CA 15-3 after 6 months correlated with FVC change ( r  =  − 0.469; p  = 0.001). Correlations with FVC change were observed in prednisone-treated HP ( r  =  − 0.514; p  = 0.005) and fibrotic HP ( r  =  − 0.417; p  = 0.007). Three-month CA 15-3 change correlated with 6-month FVC change ( r  =  − 0.599; p  

  • Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis.
    Biomarkers in medicine, 2020
    Co-Authors: Sofia A Moll, Ivo A. Wiertz, Adriane D.m. Vorselaars, Pieter Zanen, Henk J.t. Ruven, Coline H.m. Van Moorsel, Jan C. Grutters
    Abstract:

    Aim: CAncer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year follow-up were evaluated by a mixed model in 132 IPF treated with pirfenidone or nintedanib. Results: Increased baseline (median: 56 kU/l) and follow-up CA 15-3 levels were inversely associated with forced vital CApacity and diffusing CApacity of the lung for CArbon monoxide (estimates respectively: -5.21 and -4.69; p 

Ivo A. Wiertz - One of the best experts on this subject based on the ideXlab platform.

  • Change in Serum Biomarker CA 15-3 as an Early Predictor of Response to Treatment and Survival in Hypersensitivity Pneumonitis
    Lung, 2020
    Co-Authors: Sofia A Moll, Ivo A. Wiertz, Adriane D.m. Vorselaars, Henk J.t. Ruven, C. H. M. Moorsel, Jan C. Grutters
    Abstract:

    Background Hypersensitivity pneumonitis (HP) is an interstitial lung disease with a heterogeneous course of disease and treatment response. CAncer antigen 15-3 (CA 15-3), part of mucin 1, is believed to reflect epithelial cell injury and lung permeability and could be a potential biomarker for treatment response in HP. Objective To assess the value of CA 15-3 as a predictive biomarker in non-fibrotic and fibrotic HP during immunosuppressive therapy. Design Serum levels of CA 15-3 and pulmonary function tests (PFTs) were retrospectively retrieved from 48 HP patients treated with prednisone or cyclophosphamide at initiation of therapy (baseline), after 3 and 6 months. Pearson's correlation coefficient was computed to assess correlations between change in serum levels and PFT. Survival was evaluated using Kaplan–Meier curves. Results After 6 months of immunosuppressive therapy CA 15-3 levels decreased signifiCAntly compared to baseline ( p  = 0.001). Change in CA 15-3 after 6 months correlated with FVC change ( r  =  − 0.469; p  = 0.001). Correlations with FVC change were observed in prednisone-treated HP ( r  =  − 0.514; p  = 0.005) and fibrotic HP ( r  =  − 0.417; p  = 0.007). Three-month CA 15-3 change correlated with 6-month FVC change ( r  =  − 0.599; p  

  • Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis.
    Biomarkers in medicine, 2020
    Co-Authors: Sofia A Moll, Ivo A. Wiertz, Adriane D.m. Vorselaars, Pieter Zanen, Henk J.t. Ruven, Coline H.m. Van Moorsel, Jan C. Grutters
    Abstract:

    Aim: CAncer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year follow-up were evaluated by a mixed model in 132 IPF treated with pirfenidone or nintedanib. Results: Increased baseline (median: 56 kU/l) and follow-up CA 15-3 levels were inversely associated with forced vital CApacity and diffusing CApacity of the lung for CArbon monoxide (estimates respectively: -5.21 and -4.69; p